Evidence map›Paper›PMID 40631591›Full record

ArticleJournal of biomedical materials research. Part A2025

Exponentially Decreasing Antigen Release Reduces Inflammatory Markers in an Antigen-Specific Manner.

Arezoo Esrafili, Aleksandr Talitckii, Joshua Kupfer, Abhirami Thumsi, Madhan Mohan Chandra Sekhar Jaggarapu, Margaret Dugoni, Gregory Jensen, Matthew M Peet, Julianne L Holloway, Abhinav P Acharya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical materials research. Part A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Arezoo EsrafiliChemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, Arizona, USA.
Aleksandr TalitckiiAerospace and Mechanical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, Arizona, USA.
Joshua KupferChemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, Arizona, USA.
Abhirami ThumsiDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Madhan Mohan Chandra Sekhar JaggarapuDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Margaret DugoniBiomedical Engineering, School of Biological and Health Systems Engineering, Arizona State University, Tempe, Arizona, USA.
Gregory JensenChemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, Arizona, USA.
Matthew M PeetAerospace and Mechanical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, Arizona, USA.
Julianne L HollowayChemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, Arizona, USA.ORCID 0000-0001-8508-3041
Abhinav P AcharyaDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0009-0009-3836-3599

Funding

Biomaterials-based metabolic rescue of dendritic cells for vaccine designR01AI155907 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ACHARYA, ABHINAV · 2021 to 2025
$1.7M
Local immunometabolism modulating biomaterials for immunosuppressive applicationsR01AR078343 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · PI ACHARYA, ABHINAV · 2021 to 2025
$1.6M
DMS/NIGMS 1: An Experimental Mathematical Framework for understanding and Controlling Regulatory Delay in Self- Nonself Determination in the Immune System R01GM144966 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI PEET, MATTHEW M · 2021 to 2023
$600k
NIAID NIH HHS R01 AI155907NIAMS NIH HHS R01 AR078343NIGMS NIH HHS R01 GM144966NIH HHS
6 · The paper itself

Abstract

Vaccine development requires innovative approaches to improve immune responses while reducing the number of immunizations. In this study, we explore the impact of controlled antigen release on immune activation and regulation using programmable infusion pumps and biodegradable biomaterials in OT-II and wild-type mice to understand the adaptive immune response through controlled antigen delivery in the absence of adjuvant. Ovalbumin (OVA) was delivered via an exponentially decreasing profile, mimicking clearance of infection, and an exponentially increasing profile, mimicking induction of infection. Exponentially decreasing OVA delivery through infusion pumps promoted regulatory T-cell (Treg) activation in secondary lymphoid organs and suppressed pro-inflammatory T-helper type 17 (Th17) responses in blood. An exponentially increasing OVA profile enhanced central memory T-cell (TCM) populations in submandibular blood and humoral immune responses in cardiac blood serum, demonstrating distinct immune modulation based on release kinetics. OVA was also delivered using a biodegradable PLGA-PEG-PLGA (PPP) depot, which provided controlled OVA release in an exponentially decreasing pattern. PPP-OVA treatment significantly reduced the frequency of pro-inflammatory T-helper type 1 (Th1) cells while increasing CD25

Indexed as

AntigensInflammationOvalbuminAnimalsBiomarkersFemaleMiceMice, Inbred C57BLT-Lymphocytes, RegulatoryAntigensBiomarkersOvalbuminantigenmachine learningsustained releasevaccine

Identifiers

PMID40631591
PMCPMC12259016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.